Literature DB >> 28707090

Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?

J H M Driessen1,2,3,4, L M Knapen5,6, P P M M Geusens7,8, J P W van den Bergh9,7,8,10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28707090     DOI： 10.1007/s00198-017-4120-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  5 in total

1.  Immortal time bias in observational studies of drug effects.

Authors:  Samy Suissa
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-03       Impact factor: 2.890

Review 2.  DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes - A systematic review and meta-analysis.

Authors:  Jil Mamza; Carol Marlin; Cai Wang; Kamal Chokkalingam; Iskandar Idris
Journal:  Diabetes Res Clin Pract       Date:  2016-04-30       Impact factor: 5.602

3.  Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial.

Authors:  Ofri Mosenzon; Cheryl Wei; Jaime Davidson; Benjamin M Scirica; Ilan Yanuv; Aliza Rozenberg; Boaz Hirshberg; Avivit Cahn; Christina Stahre; Krzysztof Strojek; Deepak L Bhatt; Itamar Raz
Journal:  Diabetes Care       Date:  2015-09-10       Impact factor: 19.112

4.  Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.

Authors:  S Dombrowski; K Kostev; L Jacob
Journal:  Osteoporos Int       Date:  2017-04-29       Impact factor: 4.507

5.  Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.

Authors:  Johanna H M Driessen; Joop P W van den Bergh; Hein A W van Onzenoort; Ronald M A Henry; Hubert G M Leufkens; Frank de Vries
Journal:  Diabetes Obes Metab       Date:  2017-01-19       Impact factor: 6.577
  5 in total
  2 in total

Review 1.  Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.

Authors:  K Hidayat; X Du; B-M Shi
Journal:  Osteoporos Int       Date:  2019-05-27       Impact factor: 4.507

2.  Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: response to Driessen et al.

Authors:  K Kostev; S Dombrowski
Journal:  Osteoporos Int       Date:  2017-07-13       Impact factor: 4.507
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.